凝血酶原复合物浓缩物对心脏移植用血、费用及结局的影响
本研究回顾性比较了60例左心室辅助装置(LVAD)桥接心脏移植患者中,传统华法林逆转用新鲜冰冻血浆与4因子凝血酶原复合物浓缩物(PCC)对输血需求、血库费用及临床结局的影响。PCC组术中输血更少、延迟胸骨闭合更少,但血库总费用更高,两组血栓栓塞事件及院内死亡无差异。
要点
- PCC组术中新鲜冰冻血浆、冷沉淀及总血制品用量均少于无PCC组。
- PCC组延迟胸骨闭合发生率低于无PCC组(3% vs 23%,p=0.05)。
- PCC组血库总费用高于无PCC组($4,949 vs $3,677,p=0.01)。
核心结论
- 尽管费用更高,PCC减少了以LVAD桥接的心脏移植受者的输血需求及延迟胸骨闭合,作者认为这支持其替代传统华法林逆转。
研究设计与样本
- 回顾性综述纳入60例连续接受心脏移植的LVAD受者,分为无PCC组30例(接受新鲜冰冻血浆)和PCC组30例(接受PCC)。
- 比较患者特征、术中及术后输血需求、短期临床结局和血库费用,并用多元线性回归评估PCC与输血需求的关联。
主要发现
- PCC组患者更年轻(50 ± 11 vs 57 ± 13岁,p = 0.02),缺血性心肌病比例更低(23% vs 60%,p = 0.01),既往胸骨切开超过一次的比例更高(7% vs 30%,p = 0.04),术前血红蛋白更高(11.8 ± 1.8 vs 10.4 ± 1.8 g/dL,p = 0.01)。
- PCC组体外循环时间显著更短(185 vs 217分钟,p = 0.01),术中接受的新鲜冰冻血浆更少(2 vs 5单位,p = 0.03)、冷沉淀更少(0 vs 2单位,p = 0.05)、总血制品更少(9 vs 13.5单位,p = 0.03),需要延迟胸骨闭合的可能性更低(3% vs 23%,p = 0.05)。
- 多元线性回归显示,PCC与术中输血减少显著相关(β = -6.09,p = 0.02)。
- 两组血栓栓塞事件或院内死亡无差异。
- PCC组血库总费用为$4,949,无PCC组为$3,677(p = 0.01)。
临床怎么用
- 作者认为,尽管PCC费用更高,但其减少了以LVAD桥接的心脏移植受者的输血需求及延迟胸骨闭合,支持其替代传统华法林逆转。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular assist device (LVAD) recipients undergoing heart transplantation have increased bleeding risk. We compared conventional warfarin reversal with fresh frozen plasma vs 4-factor prothrombin complex concentrate (PCC) and the effect on transfusion requirements, blood bank costs, and clinical outcomes. METHODS: A retrospective review identified 60 consecutive LVAD recipients undergoing heart transplantation divided into two groups: 30 (no PCC) received fresh frozen plasma and 30 (PCC) received PCC. Patient characteristics, intraoperative and postoperative transfusion requirements, short-term clinical outcomes, and blood bank costs were compared. PCC association with transfusion requirements was assessed by multivariate linear regression. RESULTS: Patients who received PCC were younger (50 ± 11 vs 57 ± 13 years, p = 0.02), fewer had ischemic cardiomyopathy (23% vs 60%, p = 0.01), had more than one prior sternotomy (7% vs 30%, p = 0.04), and had higher preoperative hemoglobin (11.8 ± 1.8 vs 10.4 ± 1.8 g/dL, p = 0.01). The PCC group had a significantly shorter bypass time (185 vs 217 minutes, p = 0.01), received less fresh frozen plasma (2 vs 5 units, p = 0.03), cryoprecipitate (0 vs 2 units, p = 0.05), and total blood products (9 vs 13.5 units, p = 0.03) intraoperatively, and was less likely to require delayed sternal closure (3% vs 23%, p = 0.05). On multivariate linear regression, PCC was significantly associated with decreased intraoperative transfusion (β = -6.09, p = 0.02). There was no difference in thromboembolic events or in-hospital death. Total blood bank costs were $4,949 for PCC and $3,677 for no PCC (p = 0.01). CONCLUSIONS: Although more costly, PCC reduced transfusion requirements and delayed sternal closure in heart transplant recipients bridged with LVAD, justifying its use over traditional warfarin reversal.
引用
- Wu DW, Xia Y, Uelinger J, et al. Impact of Prothrombin Complex Concentrate on Blood Use, Cost, and Outcomes in Heart Transplantation. Ann Thorac Surg. 2018. PMID: 29397934. doi:10.1016/j.athoracsur.2017.10.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。